logo

Akero Therapeutics Inc. (AKRO)



Trade AKRO now with
  Date
  Headline
8/13/2021 8:12:31 AM Akero Therapeutics Q2 Loss Per Share $0.83 Vs Loss $0.57 Last Year
7/14/2021 8:11:04 AM Akero Therapeutics Appoints Judy Chou To Its Board
11/13/2020 8:07:47 AM Akero : Phase 2a BALANCED Study Shows Potential Of Efruxifermin As Foundational NASH Monotherapy
10/16/2020 7:35:47 AM Akero Therapeutics Gets European Medicines Agency Priority Medicines Designation For Efruxifermin In NASH
9/30/2020 8:02:43 AM Akero Therapeutics Completes Enrollment Of Cohort Of Cirrhotic (F4) Patients In Balanced Study
9/24/2020 7:34:44 AM Akero Plans To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design
7/7/2020 8:34:52 PM Akero Therapeutics Prices Underwritten Public Offering Of 5.23 Mln Shares At $36.00/shr
7/6/2020 7:01:38 AM Akero Therapeutics Begins Public Offering Of 4.75 Mln Shares
6/17/2020 8:06:18 AM Akero Therapeutics Doses First Patient In Expansion Of Phase 2a Trial In NASH
5/13/2020 4:10:35 PM Akero Therapeutics Q1 Loss/share $0.42 Vs. Loss $31.90 Year Ago
3/31/2020 6:02:24 AM Akero Therapeutics Says All Three AKR-001 Dose Groups In The BALANCED Study Meets Primary Endpoint